Separately, Zacks Investment Research lowered Check Cap from a buy rating to a hold rating in a research note on Tuesday, July 24th.
Shares of NASDAQ CHEK traded down $0.15 during trading hours on Tuesday, reaching $3.74. The stock had a trading volume of 27,718 shares. Check Cap has a twelve month low of $3.08 and a twelve month high of $19.78.
Check Cap (NASDAQ:CHEK) last issued its earnings results on Monday, November 5th. The medical research company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. Equities analysts anticipate that Check Cap will post -2.57 EPS for the current year.
A hedge fund recently bought a new stake in Check Cap stock. Fosun International Ltd bought a new stake in Check Cap Ltd (NASDAQ:CHEK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 127,558 shares of the medical research company’s stock, valued at approximately $517,000. Fosun International Ltd owned approximately 7.97% of Check Cap as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 17.41% of the company’s stock.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Read More: Discount Rate
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.